PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.62%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
8.49%
Other expenses change of 8.49% while AGEN maintains costs. Bruce Berkowitz would investigate efficiency.
-3.29%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-3.29%
Both companies reducing total costs. Martin Whitman would check industry trends.
-91.94%
Interest expense reduction while AGEN shows 0.09% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
3.29%
EBITDA growth below 50% of AGEN's 39.35%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
3.29%
Operating income growth below 50% of AGEN's 34.21%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
-3.29%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-27.01%
Both companies reducing tax expense. Martin Whitman would check patterns.
27.01%
Similar net income growth to AGEN's 30.84%. Walter Schloss would investigate industry trends.
No Data
No Data available this quarter, please select a different quarter.
26.90%
EPS growth 50-75% of AGEN's 42.45%. Martin Whitman would scrutinize operations.
26.90%
Diluted EPS growth 50-75% of AGEN's 42.45%. Martin Whitman would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.